U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

MedGen UID:
1718561
•Concept ID:
C5237018
•
Neoplastic Process

Definition

Diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Professional guidelines

PubMed

Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U
Cancer Treat Rev 2022 Nov;110:102443. Epub 2022 Jul 31 doi: 10.1016/j.ctrv.2022.102443. PMID: 35933930
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK
Am J Hematol 2021 May 1;96(5):617-629. Epub 2021 Mar 19 doi: 10.1002/ajh.26151. PMID: 33661537Free PMC Article
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
Moleti ML, Testi AM, Foà R
Br J Haematol 2020 Jun;189(5):826-843. Epub 2020 Mar 6 doi: 10.1111/bjh.16461. PMID: 32141616

Recent clinical studies

Etiology

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.
Renders S, Ngoya M, Finel H, Rubio MT, Townsend W, Schroers R, Novak U, Schaap N, Aljurf M, Helbig G, Collin M, Kobbe G, Huynh A, Pérez-Simón JA, Bloor A, Ghesquieres H, Sureda A, Schmitz N, Glass B, Dreger P
Blood Adv 2024 Nov 12;8(21):5571-5578. doi: 10.1182/bloodadvances.2024013152. PMID: 39213423Free PMC Article
Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O, Thörn E, Osterman P, Fors M, Dernstedt A, Forsell MNE, Erlanson M, Landfors M, Degerman S, Hultdin M
Clin Epigenetics 2024 May 21;16(1):68. doi: 10.1186/s13148-024-01680-4. PMID: 38773655Free PMC Article
Double-hit lymphoma: optimizing therapy.
Dunleavy K
Hematology Am Soc Hematol Educ Program 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. PMID: 34889402Free PMC Article
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, Ambinder R, Cheever M, Gulley JL, Goncalves PH, Wang HW, Uldrick TS, Yarchoan R
J Immunother Cancer 2021 Feb;9(2) doi: 10.1136/jitc-2020-002097. PMID: 33608378Free PMC Article
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920

Diagnosis

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.
Renders S, Ngoya M, Finel H, Rubio MT, Townsend W, Schroers R, Novak U, Schaap N, Aljurf M, Helbig G, Collin M, Kobbe G, Huynh A, Pérez-Simón JA, Bloor A, Ghesquieres H, Sureda A, Schmitz N, Glass B, Dreger P
Blood Adv 2024 Nov 12;8(21):5571-5578. doi: 10.1182/bloodadvances.2024013152. PMID: 39213423Free PMC Article
The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC, Miceska S, Gasljevic G, Boltezar L, Kloboves-Prevodnik V
Radiol Oncol 2024 Mar 1;58(1):99-109. Epub 2024 Feb 21 doi: 10.2478/raon-2024-0010. PMID: 38378036Free PMC Article
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM
Ann Oncol 2014 Nov;25(11):2211-2217. Epub 2014 Sep 5 doi: 10.1093/annonc/mdu443. PMID: 25193992Free PMC Article

Therapy

Epcoritamab: First Approval.
Frampton JE
Drugs 2023 Sep;83(14):1331-1340. doi: 10.1007/s40265-023-01930-4. PMID: 37597091
Double-hit lymphoma: optimizing therapy.
Dunleavy K
Hematology Am Soc Hematol Educ Program 2021 Dec 10;2021(1):157-163. doi: 10.1182/hematology.2021000247. PMID: 34889402Free PMC Article
Loncastuximab Tesirine: First Approval.
Lee A
Drugs 2021 Jul;81(10):1229-1233. doi: 10.1007/s40265-021-01550-w. PMID: 34143407
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Kasamon YL, Price LSL, Okusanya OO, Richardson NC, Li RJ, Ma L, Wu YT, Theoret M, Pazdur R, Gormley NJ
Oncologist 2021 Oct;26(10):879-886. Epub 2021 Jul 1 doi: 10.1002/onco.13859. PMID: 34132444Free PMC Article
Tafasitamab: First Approval.
Hoy SM
Drugs 2020 Nov;80(16):1731-1737. doi: 10.1007/s40265-020-01405-w. PMID: 32946059

Prognosis

Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O, Thörn E, Osterman P, Fors M, Dernstedt A, Forsell MNE, Erlanson M, Landfors M, Degerman S, Hultdin M
Clin Epigenetics 2024 May 21;16(1):68. doi: 10.1186/s13148-024-01680-4. PMID: 38773655Free PMC Article
The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC, Miceska S, Gasljevic G, Boltezar L, Kloboves-Prevodnik V
Radiol Oncol 2024 Mar 1;58(1):99-109. Epub 2024 Feb 21 doi: 10.2478/raon-2024-0010. PMID: 38378036Free PMC Article
Tafasitamab: First Approval.
Hoy SM
Drugs 2020 Nov;80(16):1731-1737. doi: 10.1007/s40265-020-01405-w. PMID: 32946059
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM
Br J Haematol 2019 Mar;184(5):744-752. Epub 2018 Dec 5 doi: 10.1111/bjh.15702. PMID: 30520026Free PMC Article
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920

Clinical prediction guides

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.
Renders S, Ngoya M, Finel H, Rubio MT, Townsend W, Schroers R, Novak U, Schaap N, Aljurf M, Helbig G, Collin M, Kobbe G, Huynh A, Pérez-Simón JA, Bloor A, Ghesquieres H, Sureda A, Schmitz N, Glass B, Dreger P
Blood Adv 2024 Nov 12;8(21):5571-5578. doi: 10.1182/bloodadvances.2024013152. PMID: 39213423Free PMC Article
Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O, Thörn E, Osterman P, Fors M, Dernstedt A, Forsell MNE, Erlanson M, Landfors M, Degerman S, Hultdin M
Clin Epigenetics 2024 May 21;16(1):68. doi: 10.1186/s13148-024-01680-4. PMID: 38773655Free PMC Article
The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC, Miceska S, Gasljevic G, Boltezar L, Kloboves-Prevodnik V
Radiol Oncol 2024 Mar 1;58(1):99-109. Epub 2024 Feb 21 doi: 10.2478/raon-2024-0010. PMID: 38378036Free PMC Article
The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR
Am J Hematol 2016 Oct;91(10):E436-41. Epub 2016 Aug 4 doi: 10.1002/ajh.24485. PMID: 27419920
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM
Ann Oncol 2014 Nov;25(11):2211-2217. Epub 2014 Sep 5 doi: 10.1093/annonc/mdu443. PMID: 25193992Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...